GERN — Geron Corporation

Geron Corporation Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Product Revenue: $47.2 million for Q3 2025, up from $28 million in Q3 2024, but down 3% from Q2 2025.
• Cash Position: Approximately $420 million in cash and marketable securities as of September 30, 2025, down from $503 million at the end of 2024.
• Operating Expenses: Q3 R&D expenses were $21 million (up from $20 million in Q3 2024), and SG&A expenses were $39 million (up from $36 million in Q3 2024).
• Operating Expense Guidance: For fiscal 2025, expected to be between $250 million and $260 million, lower than previous guidance of $270 million to $285 million.

2. Strategic Updates and Business Highlights:

• Product Focus: RYTELO, a telomerase inhibitor for lower-risk MDS, is viewed as a compelling treatment option with demonstrated efficacy.
• Commercial Strategy: New Chief Commercial Officer Ahmed ElNawawi has joined to enhance commercial strategy and execution.
• Market Engagement: Increased prescribing accounts by 15% to 1,150, with 150 new accounts added in Q3. The company is focusing on educating healthcare providers (HCPs) to improve patient management and increase RYTELO usage.
• Clinical Trials: Enrollment completed for the IMpactMF Phase III trial in relapsed/refractory myelofibrosis, with interim analysis expected in late 2026 and final analysis in late 2028.

3. Forward Guidance and Outlook:

• Growth Expectations: Management anticipates that 2026 will be a growth year for RYTELO as they implement strategies to improve awareness and education among HCPs.
• Long-term Vision: The company aims to maximize RYTELO's impact while advancing its pipeline, with a focus on execution and alignment within the organization.

4. Bad News, Challenges, or Points of Concern:

• Declining Demand: The 3% decline in demand for RYTELO is attributed to patient discontinuations in later treatment lines, highlighting the need for improved patient retention strategies.
• Market Education Needs: There is a recognized need to enhance awareness and understanding of RYTELO among HCPs, particularly in community settings, which is critical for establishing it as a second-line therapy.
• Competitive Landscape: The company faces competition from other treatments in the lower-risk MDS space, necessitating effective differentiation and positioning of RYTELO.

5. Notable Q&A Insights:

• Gross to Net Dynamics: CFO Michelle Robertson confirmed that the gross-to-net forecast remains in the mid- to high teens, influenced by Medicaid mix and GPO contracts.
• Sales Force Effectiveness: The sales force has been fully hired, with a focus on effectiveness rather than just headcount. The company is working on ensuring that HCPs are educated on RYTELO's use and managing patient therapy effectively.
• Timeline for Growth: CEO Harout Semerjian indicated that while there is confidence in future growth, specific timelines for revenue growth are not being provided, emphasizing a focus on execution and the need for time to see results.

Overall, Geron Corporation is focused on enhancing the commercial success of RYTELO while navigating challenges related to demand and market education. The company is optimistic about future growth driven by strategic initiatives and improved execution.